Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Preserving Access to Cost Effective Drugs Act or the PACED Act This bill prohibits patent owners from asserting tribal sovereign immunity as a defense in certain proceedings before the U.S. Patent and Trademark Office, including patent validity challenge proceedings before the Patent Trial and Appeal Board (PTAB). The prohibition also applies to court actions and proceedings before the International Trade Commission. Sovereign immunity for foreign states shall apply in the PTAB as it applies in federal court.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2018 · fourth_quarter · Health Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. Patent settlements legislation.
Client expense: $83,374 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Copyright/Patent/Trademark
S. 1390/ H.R. 5240 "STRONGER Patents Act" - entire bill H.R. 6758/P.L.115-273 "Success Act" -- entire bill S. 2514 - State Sovereign immunity as it relates to patents and the inter pares review system at USPTO - entire bill Meeting with USPTO to discuss ongoing legislation and regulatory issues
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Patent & Trademark Office (PTO), SENATE
2018 · fourth_quarter · Copyright/Patent/Trademark
Inter Partes Review (IPR) Process. H.R.7251/S.3738: Hatch-Waxman Integrity Act of 2018. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.
Client expense: $1,570,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2018 · fourth_quarter · Copyright/Patent/Trademark
H.R. 7366, the Revitalizing Amendment Motions for Patents (RAMP) Act of 2018 S. 3483/H.R. 6758, the Study of Underrepresented Classes Chasing Engineering and Science Success (SUCCESS) Act (entire bill) S. 3416, the USPTO FEES Act (entire bill) S. 3488/H.R. 6868, the American Royalties Too Act of 2018 (entire bill) H.R. 6816, the Family Movie Act Clarification Act of 2018 (entire bill) H.R. 6695, Trademark Licensing Protection Act of 2018 H.R. 6557, the Inventor Protection Act (entire bill) H.R. 6264, Restoring Americas Leadership in Innovation Act of 2018 (entire bill) S. 2601/H.R.5887, the BIG Data for IP Act (entire bill) H.R. 4171, Extension of authority to conduct telework travel expenses test programs (or TEAPP) S. 2559, the Marrakesh Treaty Implementation Act (entire bill) S. 2514, the PACED Act H.R. 5447, the Music Modernization Act of 2017 S. 2823, the Music Modernization Act of 2018 H.R. 1551, the Music Modernization Act of 2017 H.R. 4171, the Telework Enhancement Act Pilot Program (TEAPP) Extension (entire bill) S. 1948, To Abrogate Tribal Immunity in Certain Patent Claims (entire bill) H.R. 3945, the Copyright Alternative in Small-Claims Enforcement Act of 2017 (entire bill) H.R.3350, the Transparency in Music Licensing and Ownership Act (entire bill) H.R. 3301/ S. 2393, the Compensating Legacy Artists for their Songs, Service, and Important Contributions to Society (CLASSICS) Act (entire bill) S. 1390, the STONGER Patents Act of 2017 (entire bill) H.R.5340, the STONGER Patents Act of 2018 (entire bill) H.R 1914, the Performance Royalty Owners of Music Opportunity To Earn Act of 2017 (PROMOTE Act) (entire bill) H.R. 2189, the Trade Protection Not Troll Protection Act. (entire bill) S. 927, the Patents for Humanity Program Improvement Act (entire bill) H.R. 1879, the Promoting Automotive Repair, Trade, and Sales Act of 2017 (PARTS Act) (entire bill) H.R. 1836, the Fair Play Fair Pay Act of 2017 (entire bill) H.R. 1695/S. 1010, the Register of Copyrights Selection and Accountability Act (entire bill) H.R. 1450/S. 259, the No Stolen Trademarks Honored in America Act (entire bill) H.R. 890, the Copyright Office for the Digital Economy Act (CODE) (entire bill) H.R. 881/S. 2625, the Allocation for Music Producers Act (AMP Act) H.R. 720/S. 237, the Lawsuit Abuse Reduction Act H.R. 5, Regulatory Accountability Act of 2017 Issues related to USPTO operations Issues related to Department of Commerce Enterprise Services Initiative Legislative proposal on patent subject matter eligibility Issues related to proposed Lanham Act codification Draft legislation related to the Beijing Treaty Implementation
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2018 · third_quarter · Copyright/Patent/Trademark
Inter Partes Review (IPR) Process. Hatch-Waxman Integrity Act. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.
Client expense: $870,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
2018 · second_quarter · Copyright/Patent/Trademark
Inter Partes Review (IPR) Process. Hatch-Waxman Integrity Act. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.
Client expense: $900,000 · Firm income: Not reported
2018 · first_quarter · Copyright/Patent/Trademark
Inter Partes Review (IPR) process. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.
Client expense: $1,040,000 · Firm income: Not reported
2018 · third_quarter · Pharmacy
S. 974/H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180-day exclusivity periods; Federal policy relating to the Trump Administration's Fiscal Year 2019 Budget proposal to address pharmaceutical market blockages caused by parked Hatch-Waxman 180-day exclusivity periods; S. 2514, the Preserving Access to Cost Effective Drugs Act, provisions relating to the prohibition of the use of sovereign immunity to subvert review of patents; Federal policy relating to generic pharmaceutical drug prices; and Federal policy relating to generic pharmaceutical drug prices.
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Copyright/Patent/Trademark
Inter Partes Review (IPR) Process. Hatch-Waxman Integrity Act. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.
Client expense: $860,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
2018 · third_quarter · Copyright/Patent/Trademark
S. 1390 and H.R. 5340 "STRONGER Patents Act" (entire bill) S. 2514 "Preserving Access to Cost Effective Drugs Act" (PACED) (entire bill) General issues relating to patent reform and intellectual property.
Client expense: $450,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2018 · third_quarter · Copyright/Patent/Trademark
S. 1390/ H.R. 5240 "STRONGER Patents Act" - entire bill S. 2514 - State Sovereign immunity as it relates to patents and the inter pares review system at USPTO - entire bill H.R. 6758 - "Study of Underrepresented Classes Chasing Engineering and Science Success Act of 2018" - entire bill Meeting with USPTO to discuss ongoing legislation and regulatory issues, including NPRM Docket Number PTO-P-2018-0036
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Patent & Trademark Office (PTO), SENATE
2018 · third_quarter · Copyright/Patent/Trademark
S. 3483/H.R. 6758, the Study of Underrepresented Classes Chasing Engineering and Science Success (SUCCESS) Act (entire bill) S. 3416, the USPTO FEES Act (entire bill) S. 3488/H.R. 6868, the American Royalties Too Act of 2018 (entire bill) H.R. 6816, the Family Movie Act Clarification Act of 2018 (entire bill) H.R. 6695, Trademark Licensing Protection Act of 2018 H.R. 6557, the Inventor Protection Act (entire bill) H.R. 6264, Restoring Americas Leadership in Innovation Act of 2018 (entire bill) S. 2601/H.R.5887, the BIG Data for IP Act (entire bill) H.R. 4171, Extension of authority to conduct telework travel expenses test programs (or TEAPP) S. 2559, the Marrakesh Treaty Implementation Act (entire bill) S. 2514, the PACED Act H.R. 5447, the Music Modernization Act of 2017 S. 2823, the Music Modernization Act of 2018 H.R. 4706, the Music Modernization Act of 2017 S. 2334, the Music Modernization Act of 2018 H.R. 4171, the Telework Enhancement Act Pilot Program (TEAPP) Extension (entire bill) S. 1948, To Abrogate Tribal Immunity in Certain Patent Claims (entire bill) H.R. 3945, the Copyright Alternative in Small-Claims Enforcement Act of 2017 (entire bill) H.R.3350, the Transparency in Music Licensing and Ownership Act (entire bill) H.R. 3301/ S. 2393, the Compensating Legacy Artists for their Songs, Service, and Important Contributions to Society (CLASSICS) Act (entire bill) S. 1390, the STONGER Patents Act of 2017 (entire bill) H.R.5340, the STONGER Patents Act of 2018 (entire bill) H.R 1914, the Performance Royalty Owners of Music Opportunity To Earn Act of 2017 (PROMOTE Act) (entire bill) H.R. 2189, the Trade Protection Not Troll Protection Act. (entire bill) S. 927, the Patents for Humanity Program Improvement Act (entire bill) H.R. 1879, the Promoting Automotive Repair, Trade, and Sales Act of 2017 (PARTS Act) (entire bill) H.R. 1836, the Fair Play Fair Pay Act of 2017 (entire bill) H.R. 1695/S. 1010, the Register of Copyrights Selection and Accountability Act (entire bill) H.R. 1450/S. 259, the No Stolen Trademarks Honored in America Act (entire bill) H.R. 890, the Copyright Office for the Digital Economy Act (CODE) (entire bill) H.R. 881/S. 2625, the Allocation for Music Producers Act (AMP Act) H.R. 720/S. 237, the Lawsuit Abuse Reduction Act H.R. 5, Regulatory Accountability Act of 2017 Issues related to USPTO operations Issues related to Department of Commerce Enterprise Services Initiative Legislative proposal on patent subject matter eligibility Issues related to proposed Lanham Act codification Draft legislation related to the Beijing Treaty Implementation
2018 · third_quarter · Health Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $83,325 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Medicare/Medicaid
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $83,325 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Pharmacy
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $83,325 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Manufacturing
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $83,325 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Copyright/Patent/Trademark
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Client expense: $83,325 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Copyright/Patent/Trademark
S. 1390/ H.R. 5240 "STRONGER Patents Act" - entire bill S. 2514 - State Sovereign immunity as it relates to patents and the inter pares review system at USPTO Meeting with USPTO to discuss ongoing legislation and regulatory issues, including NPRM Docket Number PTO-P-2018-0036
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE
2018 · second_quarter · Copyright/Patent/Trademark
S. 1390 "STRONGER Patents Act" (entire bill) S. 2514 "Preserving Access to Cost Effective Drug Act" (PACED) (entire bill) General issues relating to patent reform and intellectual property.
Client expense: $600,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT), Treasury, Dept of
2018 · second_quarter · Copyright/Patent/Trademark
H.R. 6264, Restoring Americas Leadership in Innovation Act of 2018 (entire bill) S. 2601/H.R.5887, the BIG Data for IP Act (entire bill) H.R. 4171, Extension of authority to conduct telework travel expenses test programs (or TEAPP) S. 2559, the Marrakesh Treaty Implementation Act (entire bill) S. 2514, the PACED Act H.R. 5447, the Music Modernization Act of 2017 S. 2823, the Music Modernization Act of 2018 H.R. 4706, the Music Modernization Act of 2017 S. 2334, the Music Modernization Act of 2018 H.R. 4171, the Telework Enhancement Act Pilot Program (TEAPP) Extension (entire bill) S. 1948, To Abrogate Tribal Immunity in Certain Patent Claims (entire bill) H.R. 3945, the Copyright Alternative in Small-Claims Enforcement Act of 2017 (entire bill) H.R.3350, the Transparency in Music Licensing and Ownership Act (entire bill) H.R. 3301/ S. 2393, the Compensating Legacy Artists for their Songs, Service, and Important Contributions to Society (CLASSICS) Act (entire bill) S. 1390, the STONGER Patents Act of 2017 (entire bill) H.R.5340, the STONGER Patents Act of 2018 (entire bill) H.R 1914, the Performance Royalty Owners of Music Opportunity To Earn Act of 2017 (PROMOTE Act) (entire bill) H.R. 2189, the Trade Protection Not Troll Protection Act. (entire bill) S. 927, the Patents for Humanity Program Improvement Act (entire bill) H.R. 1879, the Promoting Automotive Repair, Trade, and Sales Act of 2017 (PARTS Act) (entire bill) H.R. 1836, the Fair Play Fair Pay Act of 2017 (entire bill) H.R. 1695/S. 1010, the Register of Copyrights Selection and Accountability Act (entire bill) H.R. 1450/S. 259, the No Stolen Trademarks Honored in America Act (entire bill) H.R. 890, the Copyright Office for the Digital Economy Act (CODE) (entire bill) H.R. 905, the You Own Devices Act (YODA) (entire bill) H.R. 881/S. 2625, the Allocation for Music Producers Act (AMP Act) H.R. 720/S. 237, the Lawsuit Abuse Reduction Act H.R. 5, Regulatory Accountability Act of 2017 Issues related to USPTO operations Issues related to Department of Commerce Enterprise Services Initiative Legislative proposal on patent subject matter eligibility Issues related to proposed Lanham Act codification Draft legislation related to the Beijing Treaty Implementation
2018 · second_quarter · Copyright/Patent/Trademark
Inter Partes Review (IPR) Process. Hatch-Waxman Integrity Act. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.
Client expense: $800,000 · Firm income: Not reported
2018 · second_quarter · Pharmacy
Issues relating to generic drug competition, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, S. 2514- PACED Act, Hatch Waxman Integrity Act
Client expense: Not reported · Firm income: $60,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Manufacturing
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $99,267 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $99,267 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Medicare/Medicaid
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $99,267 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Pharmacy
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $99,267 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Copyright/Patent/Trademark
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Client expense: $99,267 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $97,625 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Manufacturing
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $97,625 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Pharmacy
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $97,625 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Medicare/Medicaid
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Client expense: $97,625 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Copyright/Patent/Trademark
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Client expense: $97,625 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Copyright/Patent/Trademark
S. 1390 "STRONGER Patents Act" (entire bill) S. 2514 "Preserving Access to Cost Effective Drug Act" (PACED) (entire bill) General issues relating to patent reform and intellectual property.
Client expense: $1,100,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2018 · first_quarter · Copyright/Patent/Trademark
H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms S. 1681: A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services. S. 1948: A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents S. 2514: PACED Act - Provisions related to sovereign immunity and patents S. 2601: BIG Data for IP Act - Provisions related to fee-setting authority Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Bayh-Dole march-in rights policy issues
Client expense: $1,110,000 · Firm income: Not reported
2018 · first_quarter · Copyright/Patent/Trademark
H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms S. 1681: A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services. S. 1948: A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents S. 2514: PACED Act - Provisions related to sovereign immunity and patents S. 2601: BIG Data for IP Act - Provisions related to fee-setting authority Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Bayh-Dole march-in rights policy issues
Client expense: $9,960,000 · Firm income: Not reported
2018 · first_quarter · Copyright/Patent/Trademark
Inter Partes Review (IPR) process. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.2514: PACED Act.
Client expense: $970,000 · Firm income: Not reported
2018 · first_quarter · Copyright/Patent/Trademark
S. 1390/ H.R. 5240 "STRONGER Patents Act" - entire bill S. 2514 - State Sovereign immunity as it relates to patents and the inter pares review system at USPTO S. 1519/HR 2810 "National Defense Authorization Act for 2018" - report language in Senate bill on drug pricing Meeting with NIST to discuss ROI Initiative Meeting with International Trade Administration to discuss economic development issues Meeting with PTO Leg Affairs to discuss ongoing legislative business Meeting with OSTP to discuss technology transfer issues
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Natl Institute of Standards & Technology (NIST), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE
2018 · first_quarter · Pharmacy
Issues relating to generic drug competition, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, S. 2514- PACED Act
Client expense: Not reported · Firm income: $60,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Copyright/Patent/Trademark
S. 2601, the BIG Data for IP Act S. 2559, the Marrakesh Treaty Implementation Act S. 2514, the PACED Act H.R. 4706, the Music Modernization Act of 2017 S. 2334, the Music Modernization Act of 2018 H.R. 4171, the Telework Enhancement Act Pilot Program (TEAPP) Extension S. 1948, To Abrogate Tribal Immunity in Certain Patent Claims (entire bill) H.R. 3945, the Copyright Alternative in Small-Claims Enforcement Act of 2017 (entire bill) H.R.3350, the Transparency in Music Licensing and Ownership Act (entire bill) H.R. 3301/ S. 2393, the Compensating Legacy Artists for their Songs, Service, and Important Contributions to Society (CLASSICS) Act (entire bill) S. 1390, the STONGER Patents Act of 2017 (entire bill) H.R.5340, the STONGER Patents Act of 2018 (entire bill) H.R 1914, the Performance Royalty Owners of Music Opportunity To Earn Act of 2017 (PROMOTE Act) (entire bill) H.R. 2189, the Trade Protection Not Troll Protection Act. (entire bill) S. 927, the Patents for Humanity Program Improvement Act (entire bill) H.R. 1879, the Promoting Automotive Repair, Trade, and Sales Act of 2017 (PARTS Act) (entire bill) H.R. 1836, the Fair Play Fair Pay Act of 2017 (entire bill) H.R. 1695/S. 1010, the Register of Copyrights Selection and Accountability Act (entire bill) H.R. 1450/S. 259, the No Stolen Trademarks Honored in America Act (entire bill) H.R. 890, the Copyright Office for the Digital Economy Act (CODE) (entire bill) H.R. 905, the You Own Devices Act (YODA) (entire bill) H.R. 881/S. 2625, the Allocation for Music Producers Act (AMP Act) H.R. 720/S. 237, the Lawsuit Abuse Reduction Act H.R. 5, Regulatory Accountability Act of 2017 Issues related to USPTO operations Issues related to Department of Commerce Enterprise Services Initiative Legislative proposal on patent subject matter eligibility Issues related to proposed Lanham Act codification Draft legislation related to the Beijing Treaty Implementation
| Republican |
| PA |
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
Client expense: $20,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
Client expense: $20,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Administration, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Administration, Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
Client expense: $20,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)